Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide ... a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...